Drug Development
Nektar Therapeutics Receives Fast Track Designation for the Treatment of Moderate-to-Severe Atopic Dermatitis
Nektar Therapeutics
PR-02-25-NI-07Feb 10, 2025
Accelerated Drug Development for Acute Cardiovascular and Pulmonary Care
Craig Fraser
PA822Aug 25, 2021
Fast Track
Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Pancreatic Cancer
Rafael Pharmaceuticals, Inc.
PR-M11-20-012Nov 12, 2020